Medical comms - Articles

With increasing competition in the emerging world, healthcare reforms, rising customer expectations, cost constraints and the on-going challenge of successfully bringing new drugs to market, it’s perhaps fair to say that the life sciences sector is under pressure.
With increasing competition in the emerging world, healthcare reforms, rising customer expectations, cost constraints and the on-going challenge of successfully bringing new drugs to market, it’s perhaps fair to say that the life sciences sector is under pressure. It may not surprise most of those in the industry, then, to hear that the industry is also potentially facing a talent crisis.In a recent PwC Global CEO survey, a worrying 51% of CEOs from the industry reported it is becoming more difficult to attract and hire the right…

Is an employee, who is excluded from a voluntary severance scheme on discriminatory grounds, entitled to receive the full amount of severance despite the fact she kept working for her employer? We report on the case of HM Land Registry v McGlue.
Is an employee, who is excluded from a voluntary severance scheme on discriminatory grounds, entitled to receive the full amount of severance despite the fact she kept working for her employer? We report on the case of HM Land Registry v McGlue. FACTSThe employer decided to offer an “early release” scheme but decided to exclude applications from employees on a career break not due to return to work until after March 2010. The Claimant had been on a career break since March 2008 and was entitled to remain off work for up to five years. She app…

Find out how global expansion, mergers & acquisitions, and outsourcing are impacting employees' perceptions of the pharma, biotech and medical devices sectors. From market confidence to how likely professionals are to move role and what's driving these moves - take a look at our infographic for the latest insight from our US market trends report.
Read the full report: Spotlight on: Staffing and retention

Employee confidence within the pharma, biotech and medical devices sectors is growing with 4 out of 5 professionals in the US citing they have no real concerns over their future job security, according to a new report published by Real.
Employee confidence within the pharma, biotech and medical devices sectors is growing with 4 out of 5 professionals in the US citing they have no real concerns over their future job security, according to a new report published by Real.Featuring insight from hundreds of pharma, biotech and medical devices specialists from across the US, 'Spotlight on: Staffing and retention' reports that market confidence in the industry appears higher than at any other time in the last 5 years, mirroring growing consumer confidence across the US.Although there appears to b…

It was been a busy time for Parliament this spring! The Enterprise and Regulatory Reform Bill received Royal Assent on 25th April 2013, there have been more developments in the saga of Employee Shareholders and BIS has published various implementation dates for forthcoming employment legislation. We report on these parliamentary developments.
It was been a busy time for Parliament this spring! The Enterprise and Regulatory Reform Bill received Royal Assent on 25th April 2013, there have been more developments in the saga of Employee Shareholders and BIS has published various implementation dates for forthcoming employment legislation. We report on these parliamentary developments.The Enterprise and Regulatory Reform Act 2013 (ERRA)Having received Royal Assent, various implementation dat…

As part of their “growth by acquisition” strategy, the pharmaceutical recruitment company; Pharma Consulting Group (PCG) has recently acquired Surrey based CSL Recruitment and Consulting Ltd.
As part of their “growth by acquisition” strategy, the pharmaceutical recruitment company; Pharma Consulting Group (PCG) has recently acquired Surrey based CSL Recruitment and Consulting Ltd. The acquisition, which took place on the 15th of March 2013, will bring together more than 100 contractors, as well as an increasing number of permanent placements. This will give PCG a significant client portfolio, including some of the top ten Biotech’s, CRO’s and Pharmaceutical Companies in the UK and Europe, and they claim, will help them to become widely recognised as the ‘go to’ recruitment agency of cho…

As defined by Motley Fool, bioequivalence “uses a brand-name drug’s efficacy and safety data to show that any differences between it and a generic rival are statistically insignificant.”
The buzz around bioequivalent studies has been increasing in industry circles, pointing up the demand for a higher caliber of off-branded drugs. As these studies become more and more precise, generics manufacturers will gain a better foothold in the world of semi-innovative drugs, which could then put added price pressure on payers.It is safe to say that the generics drug market is not going anywhere in coming years; if anything, it is only going to grow. Accepting that reality means that organizations have to find a way to fit mandatory bioequivalence studies into their processes as they attempt to push ge…

A bad cultural fit is one of the main reasons that new employees move on within their first year.
A bad "cultural fit" is one of the main reasons that new employees move on within their first year. So when you're job hunting, remind yourself to ask the question - is this organisation's environment a good fit for me?A couple of questions up your sleeve if you get to the interview stage can be very useful to explore the suitability.1. "Why is this position available?" This should give you some insight into the previous employee's career progression or dissatisfaction.2. "Can you describe the work environment?" this should help you find out a bit about the management style at the organisation.Also, if you get the chance, connect with current or past employees through social media (preferably p…

There are 542 words that will start to impact the business world very soon.
There are 542 words that will start to impact the business world very soon. These are the 542 dictionary words applied for as generic top level domain from the Internet Authority as gTLDs at an average cost of million dollars each. What will these dictionary words achieve as global gatekeepers of cyber name identities, what power will they exert on new and established brands and who will be the new winners or losers in these global races? Which dictionary words will win gold, silver or bronze medal as top level domain names and why? Each one of the 542 proposed dictionary word top level domains will be analyzed and categorized…check the list of 542 names www.azna.com When a professional name evaluation based on th…

Universal Biotech is pleased to announce the 5th edition of Universal Biotech Innovation Prize
Who? Small & medium enterprises and Academic researchers.When? Call for proposal is open from February 4th to April 15th 2013.Which area? Innovation in life science within the following areas:Preventive & curative therapiesMedical devicesDigital HealthcareWhy should I apply?Increase your visibility at each step of selection!All candidates of the Innovation Prize are invited to the Innovation Days event that frames the awarding ceremony on October 7-9 in Paris. This event aims to bring together international actors in the field of life sciences and offers many opportunities for candidates to increase their visibility (posters, oral communication, book presentation...).Mesure your Innovation…

European pharma, biotech and medical devices companies are at risk of losing three quarters of their best people in the next 12 months according to a new report published by Real.
European pharma, biotech and medical devices companies are at risk of losing three quarters of their best people in the next 12 months according to a new report published by Real.The research, which featured insight from thousands of pharma, biotech and medical devices professionals across Belgium, France, Germany, the Netherlands, Switzerland and the UK, found that, although the vast majority of people are more confident in their job security than at any time in recent years, this confidence has led many to consider looking elsewhere.It illustrates how global factors such as the patent cliff, legislation, out…

Don’t Go Cold Turkey campaign
Almost one in five (19 per cent) current smokers admit their last quit attempt failed in less than 24 hours, with 55 per cent of quit attempts lasting less than a week. Perhaps it is no surprise then that 58 per cent don’t think they will quit at their next attempt! The average smoker has tried to quit four times before, with nearly one in ten (nine per cent) having tried 10 or more times. Despite repeated failure, 45 per cent of smokers think about giving up every day, with almost a quarter (24 per cent) thinking about it five times a day or more. The new research, consisting of an online survey of 6,271 current or former smokers, reveals 60 per cent of UK smokers want to quit, with a third planning to go ‘cold turkey’ - trying to give up immediately usi…

Leading business intelligence provider GBI Research has released its latest research report, entitled “Sales Force Effectiveness in Pharmaceuticals - Targeted Sales Models such as Enhanced Key Account Management (KAM) and Closed-Loop Marketing (CLM) Strategies Drives Sales Force Efficiency”.
Leading business intelligence provider GBI Research has released its latest research report, entitled “Sales Force Effectiveness in Pharmaceuticals - Targeted Sales Models such as Enhanced Key Account Management (KAM) and Closed-Loop Marketing (CLM) Strategies Drives Sales Force Efficiency”. The report provides key data, information and analysis of trends and practices adopted to improve sales force effectiveness in the pharmaceutical industry. The report provides a comprehensive insight into the strat…

This book provides a comprehensive resource for medical professionals on the various legal aspects involved in conducting clinical research.
This book provides a comprehensive resource for medical professionals on the various legal aspects involved in conducting clinical research. It encompasses legal and ethical issues such as duty of care, research malpractice and negligence, standards of care, informed consent, liability issues for Institutional Review Boards (IRB), conflicts of interest, insider trading and the disclosure and withholding of clinical trial results. It will also provide legal guidance on research contracts, setting up clinical trials and common legal pitfalls encountered in medical research.Click here for more details

Frequently Asked Question for Event Posting
Below is a list of questions specific to Events on Pharmiweb.com. To reveal the answer to each question, click onto the question.Can’t find an answer for a question?Contact the Pharmiweb team at help@pharmiweb.com and submit your question. You can add your event details for nothing here. Of course we approve them before they go live, and they need to be appropriate to the pharmaceutical industry. Unfortunately you can't right now. But if you email help@pharmiweb.com we can make any changes for you. If the Changes are major, it may be easier to post it again then email help@pharmiweb.com to tell us to delete the old one. You will need to drop an email to editor@pharmiweb.com with the details of the event and your required change. This will normall…

Frequently asked questions about Press Releases
Below is a list of questions specific to Press Releases on Pharmiweb.com. To reveal the answer to each question, click onto the question.Can’t find an answer for a question?Contact the Pharmiweb team at help@pharmiweb.comand submit your question.Once its submitted, we get a notification and check it out and approve it before it goes live. Its worth noting that our press releases do get picked up by a number of newsfeed services such as Moreover, so entries here can quite quite substantial exposure. ADD PRESS RELEASE HEREUnfortunately at the moment, you can't! so just drop your amendments on an email to help@pharmiweb.com and we will make the changes for you.Normally, press releases are approved within 24 hours if posted during the week. We do…

Candidate frequently asked questions
Below is a list of questions specific to posting events on Pharmiweb.com. To reveal the answer to each question, click onto the question.Can’t find an answer for a question?Contact the Pharmiweb team at help@pharmiweb.com and submit your question.Yes you can! If you search and save your job search (from the search results page - using  the "send me jobs like this everyday") - your daily email has an RSS feed link too. Simply subscribe to this on your favourite RSS reader.There is currently no way to see a list the jobs you have applied for. However, for each application, you will receive an email confirmation from PharmiWeb.com. We are currently working on a new feature that will allow this.Each job alert email has a link at the bottom of to cancel…

Five years ago, recruiters faced an enormous challenge when trying to attract candidates for senior level positions within generics pharmaceutical companies – nobody wanted to work for a generics business.
Five years ago, recruiters faced an enormous challenge when trying to attract candidates for senior level positions within generics pharmaceutical companies – nobody wanted to work for a generics business. Come 2013, we are seeing top level candidates from research based Pharma companies actively seek out a change to generics – what has changed and what is it like making the change into a generics company? Andy Stevens from Blue Pelican Pharma gives his views:“The rise of the attractiveness of a career in generics is a reflection of several factors. Firstly, the patent cliff suffered…

The year 2012 will soon pass into history, and what a year it was for biopharmaceuticals. In the United States, the Supreme Court affirmed the new healthcare reform law and exempted pharma companies from sales force overtime rules, the Food & Drug Administration (FDA) approved the first obesity drug in 13 years with Belviq, and billions of dollars changed hands as a result of government settlements.
The year 2012 will soon pass into history, and what a year it was for biopharmaceuticals. In the United States, the Supreme Court affirmed the new healthcare reform law and exempted pharma companies from sales force overtime rules, the Food & Drug Administration (FDA) approved the first obesity drug in 13 years with Belviq, and billions of dollars changed hands as a result of government sett…

Few, if any, of those running life sciences companies in the UK or any of its peer economies in the West will look back on this point in history with great affection.
Few, if any, of those running life sciences companies in the UK or any of its peer economies in the West will look back on this point in history with great affection. The pharmaceuticals sector is under pressure all round – from increasing competition in the emerging world, from healthcare reforms and the effects of austerity and from the ongoing challenges of bringing drugs successfully to market. So, with so many problems already competing for managerial attention, it’s perhaps no surprise that a significant talent crisis looming in the background seems to have gone largely ignored.When headline writers keep telling us that…